Career Achievements

Professional Highlights

A career defined by scientific leadership, strategic transformation and measurable enterprise impact.

Executive Highlights

A Distinguished Executive Career

  • 35+ years of pharmaceutical industry experience spanning scientific leadership, analytical and formulation development, respiratory drug development, pharmaceutical operations, global procurement, strategic sourcing, supplier management, and executive leadership.

  • Chief Scientific Officer at Knightpoint Group LLC, responsible for strategic scientific direction, technology development, external partnerships, CDMO programmes, pre-clinical development, and commercialization strategy.

  • Led programmes supporting two major respiratory drugs and a repurposed treatment for paediatric Eosinophilic Esophagitis, addressing an unmet medical need.

  • Designed, negotiated, and led CDMO work programmes supporting patented respiratory/device technologies through pre-clinical development and proof of concept.

  • Built strategic alliances that strengthened company value and supported broader scientific and commercial objectives.

  • Contributed to a 50% increase in asset valuation over 18 months, following strategic scientific and development work and subsequent investment-bank evaluation.

  • Led the Lactose New Zealand project, reporting to the President of Global Manufacturing & Supply.

  • Developed the project justification and $35 million funding proposal for CEO consideration, connecting technical and operational requirements with capital investment and enterprise strategy.

  • Extensive experience connecting scientific innovation, operational execution, capital investment, and commercial priorities.

  • Mylan leadership spanning 2013–2019, with responsibility for regional packaging, raw materials, and excipients, as well as global category leadership.

  • Developed global sourcing strategies covering pharmaceutical delivery devices from auto-injectors through respiratory drug-delivery technologies.

  • Managed a medical-device portfolio representing approximately $500 million in spend.

  • Built and led cross-functional teams across EMEA with senior stakeholder support.

  • Implemented Supplier Relationship Management (SRM) from R&D development through commercial launch.

  • Led procurement governance, contract-management, approval processes, and supply-risk management initiatives.

  • Delivered $4.8 million in packaging PPV savings while supporting the development and integration of acquired manufacturing sites.

  • Experience leading supplier consolidation and strategic sourcing for a $3 billion global respiratory product portfolio at GlaxoSmithKline.

  • Delivered more than £7.2 million in validated savings through global R&D sourcing and supplier transformation.

  • Led global R&D laboratory sourcing across UK and US operations.

  • Strengthened supplier performance through strategic Supplier Relationship Management, including the Fisher Scientific relationship.

  • Managed complex supply continuity challenges, including the global Acetonitrile shortage.

  • Earlier scientific career at GSK included analytical chemistry, formulation development, pMDI, DPI, inhalation product development, respiratory drug development, and oral solid-dose technologies.

  • Progressed through roles of increasing responsibility from scientific and formulation leadership into global sourcing, procurement, and executive pharmaceutical leadership.

  • Consulting experience across strategic sourcing, procurement, facilities, insurance, laboratory operations, packaging, pharmaceutical devices, and business development.

  • Experience working directly with senior stakeholders across R&D, manufacturing, finance, procurement, supply chain, commercial operations, and executive leadership.

  • Strong combination of scientific depth and commercial/operational discipline, enabling him to translate technical opportunities into development, investment, and commercialization pathways.

  • Demonstrated ability to lead cross-functional transformation, strategic partnerships, supplier ecosystems, operational improvement, and enterprise value creation.

  • Leadership philosophy centered on scientific rigor, commercial discipline, accountability, collaboration, evidence-based decision-making, and disciplined execution.

  • Brings an enterprise perspective across the pharmaceutical lifecycle, from scientific research and formulation through development, sourcing, manufacturing, commercialization, and strategic investment.

Frequently Asked Questions

Common Questions

  • What does Andrew Burgess specialize in?
    Andrew is a senior pharmaceutical executive with more than 35 years of experience spanning scientific leadership, drug development, formulation, respiratory technologies, pharmaceutical operations, global procurement, and strategic sourcing.

  • What was Andrew's role at Mylan?
    From 2013–2019, Andrew held global and regional leadership responsibilities across packaging, raw materials, and excipients, as well as medical-device sourcing. His work included supplier strategy, SRM, supply-risk management, procurement governance, and a medical-device portfolio representing approximately $500 million in spend.

  • What was Andrew's experience at GlaxoSmithKline?
    Andrew spent more than three decades at GSK across scientific, formulation, respiratory development, sourcing, and procurement leadership roles. He progressed from scientific and formulation responsibilities into global sourcing leadership, including R&D laboratory sourcing and raw-material procurement.

  • How does Andrew approach leadership?
    His leadership philosophy is based on scientific rigor, commercial discipline, accountability, collaboration, evidence-based decision-making, and disciplined execution. He focuses on bringing scientific, operational, commercial, and financial perspectives together to achieve enterprise objectives.

  • What differentiates Andrew as an executive?
    Andrew combines deep scientific expertise with commercial and operational leadership. His career spans the pharmaceutical lifecycle—from scientific research and formulation through development, sourcing, manufacturing, strategic partnerships, investment planning, and commercialization—allowing him to connect technical opportunities with broader enterprise value.

  • What types of executive opportunities does Andrew Burgess consider?

    Andrew considers Chief Scientific Officer, Chief Strategy Officer, and senior pharmaceutical executive opportunities where he can apply his experience across scientific strategy, drug development, pharmaceutical operations, strategic sourcing, innovation, and enterprise value creation. He is particularly interested in leadership roles that combine scientific innovation with commercial strategy, operational transformation, strategic partnerships, and long-term growth.

  • What is Andrew's current role?
    He serves as Chief Scientific Officer at Knight point Group LLC, where he leads strategic scientific direction, external partnerships, CDMO programmed, pre-clinical development, and commercialization-related initiatives.

  • What are Andrew's key areas of expertise?
    His expertise includes scientific strategy, pharmaceutical R&D, respiratory drug development, formulation and drug delivery, pharmaceutical operations, global procurement, strategic sourcing, supplier relationship management, CDMO partnerships, manufacturing, operational transformation, and enterprise value creation.

  • What major value-creation achievements has Andrew delivered?
    His documented achievements include contributing to a 50% increase in asset valuation over 18 months, delivering $4.8 million in packaging savings, generating more than £7.2 million in validated savings, and leading sourcing strategies associated with a medical-device portfolio of approximately $500 million in spend.

  • What is the Lactose New Zealand project?
    Andrew led the Lactose New Zealand project, reporting to the President of Global Manufacturing & Supply. He developed the project justification and a $35 million funding proposal for CEO consideration, connecting technical and operational requirements with capital investment and enterprise priorities.

  • What is Andrew's respiratory pharmaceutical experience?
    His scientific career includes extensive experience in pMDI and DPI technologies, inhalation formulation, respiratory drug development, and respiratory drug-delivery systems. He has also supported the development of two major respiratory drugs and a repurposed treatment for paediatric Eosinophilic Esophagitis.